Eradicating leukaemic stem cells by targeting the arginine methyltransferase PRMT5

通过靶向精氨酸甲基转移酶 PRMT5 根除白血病干细胞

• 批准号: nhmrc : GNT1086662
• 负责人: A/Pr Andrew Wei
• 金额: $ 74.24万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/eradicating-leukaemic-stem-methyltransferase-prmt5/1345667
• 关键词: Eradicating; leukaemic; stem; cells; targeting

Acute leukemia is a devastating cancer arising from primitive cells in the bone marrow called stem cells. We have identified a protein (PRMT5) that is highly expressed in leukemia stem cells. Our preliminary experiments suggest that blocking the function of this protein with a novel drug can stop the growth of these cells. This project will use a variety of mouse models of acute leukemia to determine how PRMT5 keeps stem cells alive and whether this drug will be a valuable new treatment.

急性白血病是一种毁灭性的癌症，起源于骨髓中的原始细胞，称为干细胞。我们已经确定了一种在白血病干细胞中高表达的蛋白质(PRMT5)。我们的初步实验表明，用一种新药阻断这种蛋白质的功能可以阻止这些细胞的生长。该项目将使用各种急性白血病的小鼠模型来确定PRMT5是如何保持干细胞存活的，以及这种药物是否将成为一种有价值的新疗法。